Cytogenix (fka CYGX)

[kobisan]

Unrealistic expectations, JJ?

I've been an investor for 8 1/2 years and I've seen the IND for Simplivir pushed back several years already. When the PRs about an IND for CY301 first came out, there was no talk about how the product wouldn't be viable because of the high cost of DNA plasmid. That story came out some time after synDNA was developed.

If it weren't for synDNA, this company would be toast. It's the only reason why I'm still invested in CYGX. So let's be realistic, JJ, and admit that the only thing that's going to make money for CYGX in the near future is licensing and sales of synDNA. CYGX needs to concentrate on capturing as much market share for DNA plasmid mfg as they can through partnerships with other companies. Contracts with the govt would be a good thing too.